NEXTCURE, INC Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer
NEXTCURE, INC (NXTC) had Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer of $0 as of 2026-06-30, per its S-4 filed 2026-08-18.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger · last filed 2026-08-18
- 2026-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
- 2025-06-30: Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer $0.00.
| Period end | Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer |
|---|---|
| 2026-06-30 | $0.00 S-4 · filed 2026-08-18 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-05 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 |
| 2024-12-31 | $0.00 10-K · filed 2025-03-06 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $19.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $7.00M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $7.50M 10-K · filed 2024-03-21 |
| 2023-09-30 | $18.40M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $19.40M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $52.00M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $91.80M 10-K · filed 2023-03-02 |
| 2022-09-30 | $59.00M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $33.20M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |